Evidence map›Paper›PMID 30937279›Full record

ReviewJournal of bone oncology2019

Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management.

Stella D'Oronzo, Robert Coleman, Janet Brown, Francesco Silvestris

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of bone oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 176 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
176citing papers in PubMed, 1 pooled it
8.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

176 citing papers in PubMed, 1 synthesis or guideline pooled it, 251 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. The role of surgical timing in survival of patients with spinal metastases.International journal of clinical oncology · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

116 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Stella D'OronzoMedical Oncology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, P.za Giulio Cesare, 11, 70124 Bari, Italy.
Robert ColemanAcademic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Whitham Rd, Sheffield S10 2SJ, England, UK.
Janet BrownAcademic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Whitham Rd, Sheffield S10 2SJ, England, UK.
Francesco SilvestrisMedical Oncology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, P.za Giulio Cesare, 11, 70124 Bari, Italy.
University of Bari Aldo Moro · ITUniversity of Sheffield · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone metastases (BM) are a common complication of cancer, whose management often requires a multidisciplinary approach. Despite the recent therapeutic advances, patients with BM may still experience skeletal-related events and symptomatic skeletal events, with detrimental impact on quality of life and survival. A deeper knowledge of the mechanisms underlying the onset of lytic and sclerotic BM has been acquired in the last decades, leading to the development of bone-targeting agents (BTA), mainly represented by anti-resorptive drugs and bone-seeking radiopharmaceuticals. Recent pre-clinical and clinical studies have showed promising effects of novel agents, whose safety and efficacy need to be confirmed by prospective clinical trials. Among BTA, adjuvant bisphosphonates have also been shown to reduce the risk of BM in selected breast cancer patients, but failed to reduce the incidence of BM from lung and prostate cancer. Moreover, adjuvant denosumab did not improve BM free survival in patients with breast cancer, suggesting the need for further investigation to clarify BTA role in early-stage malignancies. The aim of this review is to describe BM pathogenesis and current treatment options in different clinical settings, as well as to explore the mechanism of action of novel potential therapeutic agents for which further investigation is needed.

Indexed as

ActRIIA, activin-A type IIA receptorBC, breast cancerBM, bone metastasesBMD, bone mineral densityBMPs, bone morphogenetic proteinsBMSC, bone marrow stromal cellsBone metastasesBone targeting agentsBPs, bisphosphonatesBTA, bone targeting agentsBTM, bone turnover markersCCR, chemokine-receptorCRPC, castration-resistant PCCXCL-12, C–X–C motif chemokine-ligand-12CXCR-4, chemokine-receptor-4DFS, disease-free survivalDKK1, dickkopf1EBC, early BCECM, extracellular matrixET-1, endothelin-1FDA, food and drug administrationFGF, fibroblast growth factorGAS6, growth-arrest specific-6GFs, growth factorsGnRH, gonadotropin-releasing hormoneHER-2, human epidermal growth factor receptor 2HR, hormone receptorIL, interleukinLC, lung cancerMAPK, mitogen-activated protein kinaseMCSF, macrophage colony-stimulating factorMCSFR, MCSF receptorMIP-1α, macrophage inflammatory protein-1 alphaMM, multiple myelomaMPC, malignant plasma cellsmTOR, mammalian target of rapamycinN-BPs, nitrogen-containing BPsNF-κB, nuclear factor-κBnon-N-BPs, non-nitrogen containing BPsONJ, osteonecrosis of the jawOS, overall survivalOsteotropic tumorsPC, prostate cancerPDGF, platelet-derived growth factorPFS, progression-free survivalPIs, proteasome inhibitorsPSA, prostate specific antigenPTH, parathyroid hormonePTH-rP, PTH related proteinQoL, quality of lifeRANK-L, receptor activator of NF-κB ligandRT, radiation therapySkeletal related eventsSREs, skeletal-related eventsSSEs, symptomatic skeletal eventsTGF-β, transforming growth factor βTKIs, TK inhibitorsTK, tyrosine kinaseTNF, tumornecrosis factorv-ATPase, vacuolar-type H+ ATPaseVEGFR, VEGF receptorVEGF, vascular endothelial growth factor

Identifiers

PMID30937279
PMCPMC6429006
OpenAlexW2899834008

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.